Editor's Essential Reading ➡️ Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases ow.ly/VN3C50QHi3X

⁦Paul Moayyedi inspiring us Canadian gastroenterologists with his President's address at #CDDWCLM2024!

3/3 TRIUMPH study: tofacitinib 10 mg twice a day was effective in steroid refractory ASUC (including in biologic failures): 57% 7 day clinical response. A good 2nd line option in ASUC. Will this ever replace IFX as a possible first line treatment of ASUC? Neeraj Narula

Hit the target? Our latest paper in CGH finds achieving MM-SES-CD <22.5 and SES-CD <4 in Crohn's disease is associated with low risk of disease progression and is a suitable target in clinical trials and practice for endoscopic healing. doi.org/10.1016/j.cgh.…

Check out our new thought provoking study🔥🔥 Do 💉have different effect for distal vs extensive UC. TOFA & IFX better for extensive UC>distal. eClinicalMedicine – The Lancet Discovery Science The Lancet Vipul Jairath MBChB DPhil Parambir Dulai Neeraj Narula Laurent Peyrin-Biroulet Christopher Ma MD MPH thelancet.com/journals/eclin…

@jamiezhen presenting exciting news on the role of digital health monitoring in IBD. Better patient satisfaction and improved health outcomes. @farncombe_GI @FFDHRI Neeraj Narula McMaster University Department of Medicine Crohn's and Colitis Canada

Honoured to have mentored by the GOAT in IBD research. Congrats on the research mentor award Jean-Frederic Colombel, so well deserved! Ryan Ungaro MD MS Joana Torres

So proud of Emily Wong for all her amazing accomplishments, including this study looking at biomarkers which predict subsequent IBD development from the PURE study PHRI.ca Population Health Research Institute 🇨🇦 John K. Marshall MD Paul Moayyedi #EmilyWong #SalimYusuf #GuillamePare Digestive Disease Week

Dr Neeraj Narula presenting results of TRIUMPH study of tofacitinib 10 mg BID for acute severe UC— 58% responded by day 7 and approx 1/3 were in steroid free remission by 3 months Neeraj Narula #DDW2024

Now in AJG - The American Journal of Gastroenterology: Achieving resolution of rectal bleeding in acute severe UC in associated with 6 months steroid-free clinical remission and endoscopic improvement. Finally a pragmatic patient-reported treatment target for acute severe UC! journals.lww.com/ajg/abstract/9…

According to data 📈 presented by Neeraj Narula at #DDW2024: Nearly 6️⃣0️⃣% of patients with acute severe #ulcerativecolitis responded to #Xeljanz 10 mg 💊 twice daily 👉🏻by day 7️⃣, 👉🏻with one-third of patients in steroid-free remission by 6️⃣ months 🗓️ healio.com/news/gastroent…

Glad to be a part of another successful The Canadian IBD Research Consortium (CIRC) study. Ustekinumab persistence in bio-naive Crohn's disease remarkably high in the real-world, approaching 94% persistence at one-year! Congrats Talat Bessissow Christopher Ma MD MPH Vipul Jairath MBChB DPhil sciencedirect.com/science/articl…

Adaptive #steroid #tapering impedes corticosteroid-free remissions compared to forced tapering in clinical trials of #UC Neeraj Narula Parambir Dulai Vipul Jairath MBChB DPhil academic.oup.com/ecco-jcc/advan…

Early Biologic Treatment Decreases Risk of Surgery in Crohn’s Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis. In previous meta-analyses, early biological use has been associated with a lower relapse rate and higher clinical remission. This study

In a randomized trial in patients with Crohn’s disease in whom anti-TNF therapy had failed, risankizumab was more effective than ustekinumab in achieving clinical and endoscopic remission. Read the full SEQUENCE trial results: nej.md/46dtnFY

This paper found MM-SES-CD <22.5 and SES-CD <4 are pragmatic treatment targets for endoscopic healing of #Crohn's disease which associated with low-risk of longer term disease progression Neeraj Narula ow.ly/r09H50SUc3P

How would you rank novel therapies such as etrasimod, risankizumab, mirikizumab, and guselkumab in UC ❓ What treatment 🎯 you are interested in ❓ Our recent NMA at CGH cghjournal.org/article/S1542-… Talat Bessissow Vipul Jairath MBChB DPhil Beatriz Gros #MondayNightIBD Shrinivas Bishu

Time to stop lumping together all patients with prior biologic 'exposure'? Our latest work in #JCC Oxford Academic found outcomes of IBD patients with prior biologic intolerance to be better than those with prior failure. academic.oup.com/ecco-jcc/advan…